The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice

被引：0
|
作者：
Gallo, Linda A. [1 ]
Ward, Micheal S. [1 ]
Fotheringham, Amelia K. [1 ]
Zhuang, Aowen [1 ]
Koepsell, Hermann [2 ]
Vallon', Volker [3 ,4 ]
Pollock, Carol [5 ]
Panchapakesan, Usha [5 ]
Forbes, Josephine M. [1 ]
机构：
[1] Univ Queensland, Mater Res Inst, Woolloongabba, Qld, Australia
[2] Univ Wurzburg, Wurzburg, Germany
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] VA San Diego Healthcare Syst, San Diego, CA USA
[5] Univ Sydney, Kolling Inst Med Res, St Leonards, NSW, Australia
来源：
FASEB JOURNAL | 2016年 / 30卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
740.18
引用
收藏
页数：2
相关论文
共 50 条
  • [21] SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice
    Gong, Qiaoyun
    Zhang, Rulin
    Wei, Fang
    Fang, Junwei
    Zhang, Jingfa
    Sun, Jun
    Sun, Qian
    Wang, Haiyan
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 152
  • [22] SGLT2-i improves markers of islet endothelia cell function in db/db diabetic mice
    Hogan, Meghan F.
    Hackney, Daryl J.
    Aplin, Alfred C.
    Mundinger, Thomas O.
    Larmore, Megan J.
    Castillo, Joseph J.
    Esser, Nathalie
    Zraika, Sakeneh
    Hull, Rebecca L.
    JOURNAL OF ENDOCRINOLOGY, 2021, 248 (02) : 95 - 106
  • [23] Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice
    Bamba, Ryo
    Okamura, Takuro
    Hashimoto, Yoshitaka
    Majima, Saori
    Senmaru, Takafumi
    Ushigome, Emi
    Nakanishi, Naoko
    Asano, Mai
    Yamazaki, Masahiro
    Takakuwa, Hiroshi
    Hamaguchi, Masahide
    Fukui, Michiaki
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2022, 13 (01) : 574 - 588
  • [24] Rosiglitazone Increases Renal Neprilysin Protein Expression and Decreases Albuminuria In Db/db Diabetic Mice
    Chodavarapu, Harshita
    Kablan, Narges
    Salem, Esam
    Elased, Khalid M.
    HYPERTENSION, 2011, 58 (05) : E125 - E125
  • [25] POTENTIAL ROLE FOR KETONE BODY METABOLISM IN AN SGLT2 INHIBITOR-MEDIATED ANTI-ALBUMINURIC EFFECT IN TYPE 2 DIABETIC DB/DB MICE
    Kume, Shinji
    Tomita, Issei
    Yamahara, Kosuke
    Yasuda-Yamahara, Mako
    Takeda, Naoko
    Osawa, Norihisa
    Chin-Kanasaki, Masami
    Kaneko, Tatsuroh
    Pieper, Michael
    Araki, Shin-Ichi
    Maegawa, Hiroshi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 504 - 504
  • [26] Combination of an SGLT2 Inhibitor (BI 38335) with Linagliptin: Beneficial Effects on Islet Function and Insulin Sensitivity in db/db Mice
    Chen, Lihua
    Klein, Thomas
    Leung, Po Sing
    DIABETES, 2011, 60 : A539 - A539
  • [27] A DPP-4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db/db diabetic mice, comparison with a SGLT2 inhibitor and pioglitazone
    Terasaki, M.
    Nagashima, M.
    Hiromura, M.
    Notomi, K.
    Hirano, T.
    DIABETOLOGIA, 2014, 57 : S354 - S354
  • [28] The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy
    Hualin Xu
    Jie Fu
    Qiang Tu
    Qingyun Shuai
    Yizhi Chen
    Fuyun Wu
    Zheng Cao
    Journal of Physiology and Biochemistry, 2024, 80 : 27 - 39
  • [29] The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy
    Xu, Hualin
    Fu, Jie
    Tu, Qiang
    Shuai, Qingyun
    Chen, Yizhi
    Wu, Fuyun
    Cao, Zheng
    JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, 2024, 80 (01) : 27 - 39
  • [30] Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression
    Abbas, Noha A. T.
    El Salem, Amal
    Awad, Mohammed M.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2018, 391 (12) : 1347 - 1360
12345